IN8bio, Inc. (INAB) vs Pasithea Therapeutics Corp. (KTTA)
A side-by-side comparison of IN8bio, Inc. and Pasithea Therapeutics Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
INAB
IN8bio, Inc.
$1.42HealthcareDelayed quote: Oct 6, 2026, 10:32 AM EDT
KTTA
Pasithea Therapeutics Corp.
$0.45HealthcareDelayed quote: Oct 6, 2026, 10:37 AM EDT
Total return — INAB vs KTTA
growth of $100 · dividends reinvested · last 5yINAB -99.4% (-64.2%/yr)KTTA -99.4% (-63.6%/yr)KTTA compounded faster over this window
INAB KTTA
INAB vs KTTA: by the numbers
- •KTTA is the larger company ($15M vs $14M market cap).
Metrics side by side
Valuation
| Metric | INAB | KTTA |
|---|---|---|
| P/B ratio | 0.74 | 0.30 |
Profitability
| Metric | INAB | KTTA |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -101.66% | -42.72% |
| ROIC | -91.74% | -48.04% |
Growth (annualized)
| Metric | INAB | KTTA |
|---|---|---|
| Total return CAGR (5Y) | -62.88% | -61.48% |
Frequently asked
- How have INAB and KTTA total returns compared?
- Over the past 5 years, INAB delivered -62.88% and KTTA delivered -61.48% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.